trending Market Intelligence /marketintelligence/en/news-insights/trending/qLkena3BKCvO8YuOGgz1_Q2 content esgSubNav
In This List

Cellectar Biosciences secures patent for radiotherapy compounds

Case Study

Identifying PPE Suppliers During the Pandemic

Blog

Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage

Video

COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021

Blog

Corporate Credit Risk Trends in Developing Markets: A Loss Given Default (LGD) Perspective


Cellectar Biosciences secures patent for radiotherapy compounds

Cellectar Biosciences Inc. secured patents covering the method of use for its CLR 131 and CLR 125 compounds in radiotherapy in the U.S.

The patent runs through 2025 and covers radiotherapy applications for multiple tumor types, including lung and intestinal.

Cellectar also recently received a patent covering the method of use for CLR 1603 to treat breast, lung, colorectal and prostate cancers, as well as associated cancer stem cells.